[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipidemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipidemia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100609824","phase-3-a-study-to-evaluate-the-effect-of-obicetrapibezetimibe-10-mg-fixed-dose-combination-or-obicetrapib-10-mg-daily-on-top-of-guideline-recommended-lipid-lowering-therapy-in-participants-with-type-2-diabetes-andor-metabolic-syndrome-100609824",false,"NCT07219602","A Study to Evaluate the Effect of Obicetrapib\u002FEzetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome","A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and\u002For Metabolic Syndrome (RUBENS Trial)","RUBENS","Inclusion Criteria:\n\n* fasting serum LDL-C ≥ 70 mg\u002FdL (≥1.81 mmol\u002FL)\n* Have fasting TG ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL)\n* Know diagnosis of T2DM OR have metabolic syndrome defined as fasting TG ≥150 mg\u002FdL (≥1.7mmol\u002FL) and \\\u003C400 mg\u002FdL (\\\u003C4.5 mmol\u002FL) and at least 2 risk factors\n* Are on stable guideline-recommended lipid-lowering therapy\n* Estimated glomerular filtration rate ≥15 mL\u002Fmin\u002F1.73 m2\n\nExclusion Criteria:\n\n* Have current or any previous history of New York Heart Association class III or IV heart failure or left ventricular ejection fraction \\\u003C30%\n* Have been hospitalized for heart failure within 5 years prior to Screening\n* Have uncontrolled severe hypertension\n* Have a formal diagnosis of homozygous familial hypercholesterolemia\n* HbA1c ≥10.0% (≥0.100 hemoglobin fraction) or a fasting glucose ≥270 mg\u002FdL (≥15.0 mmol\u002FL) at Screening\n* active liver disease","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and\u002For Type 2 Diabetes Mellitus.",[27,28,29],"Lipidemia","Type 2 Diabetes (T2DM)","Metabolic Syndrome (MetS)","RECRUITING","2026-03-06",{"date":33,"type":34},"2026-03-10","ACTUAL",{"date":36,"type":34},"2025-12-11",{"date":38,"type":21},"2028-06",{"name":40,"class":41},"NewAmsterdam Pharma","INDUSTRY",20]